Healthcare Webinars

In general, large pharmaceutical companies favor adopting functional service provider (FSP) models over full-service outsourcing across their clinical and research and development (R&D) operations. FSPs allow for greater oversight and can offer better outcomes regarding accelerated delivery and higher quality data. Can smaller companies benefit from working with a contract research organization (CRO) through an FSP model? During this webinar, participants will delve into the explorative realm of FSP models, particularly how to curate them for mid-sized companies to elevate their clinical trial performance.

Healthy sleep could be beneficial for people who have Down’s syndrome as they get older. The University of Cambridge is running a research study that looks at how sleep might affect the brain and memory. If we can understand more about sleep and aging, we can develop better treatments or lifestyle approaches that will help people who have Down’s syndrome stay healthier for longer. Join us for this online webinar to speak with Dr. Stephanie Brown about the research and find out more about how to get involved.

An update on the bigger picture prescribing data for nutritional borderline substances and what new insights and opportunities this provides to ensure their appropriate and sustainable future use.

Webinar Registration Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Join Professor Alan Carson, Consultant Neuropsychiatrist and Honorary Professor at the University of Edinburgh, to learn more about how to get your Brain Health research published! This webinar will provide insights for all researchers at all career stages, from Early Career Researchers to Senior Scientists. Date: February 2nd 2024 Time:13:00-14:00 GMT If you have any questions, please get in touch with brainhealtharc@glasgow.ac.uk

Antimicrobial resistance (AMR) is a critical threat with far-reaching consequences. Join our webinar to enhance awareness of current AMR resource mobilisation in LMICs and generate recommendations to inform the UNGA high-level meeting on AMR. Panelists include Dr. Tim Jinks, Dr. Mirfin Mpundu, Dr. Satoko Otsu, Prof. Judtih Torimiro, and representatives from Danish Foreign Ministry, German Federal Ministry for Economic Cooperation and Development, and Swedish Government.

Join us for OASI and Disability: Employment, Rights and Assessment online event. An OASI and Anal Incontinence (AI) are devastating conditions, which can impact on more than just a women’s physical body. Women often suffer in silence and find it difficult to discuss the condition to their family, let alone their workplace. This can be a huge financial burden if injured women cannot return to work. With the recent recognition of the difficulty of working whilst in the perimenopause and menopause, The MASIC Foundation & leading speakers consider the barriers to working and what can be done to help women with an OASI or AI.

Introducing By the Numbers, a new webinar series presented by C3 Affiliate Member SpringBoard Data Management. Each month you'll get insights into emerging trends in the cannabis sector, as well as an opportunity to pose questions about the latest industry data. Join us January 31 at 3pm ET for a look back at the key trends from 2023.

Explore this webinar on a peptide ligand, called molecular guidance system 5 (MGS5), targeting N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA in cancer, enhancing early detection and advancing liposome-based immunotherapy for pancreatic cancer. Glycosylation is a post-translation modification that is commonly altered in cancer, playing fundamental roles in cell signaling, cell migration and invasion, immune modulation and metastasis. Neu5Ac-Sialyl LewisA (CA19-9), part of the Lewis blood antigen family, is a well-studied blood biomarker that is Food and Drug Administration (FDA) approved for the detection of pancreatic cancer. However, its counterpart, N-glycolylneuraminic acid (Neu5Gc)-Sialyl LewisA, is under study in human malignancies due to the inactivation of the cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH) gene and the absence of Neu5Gc-Sialyl LewisA specific targeting molecules. Read more... Utilizing a novel screening platform, a peptidic ligand (MGS5) was identified to selectively bind and rapidly internalize into cancer cells. Target identification and validation studies showed MGS5 to be highly specific for the Neu5Gc version of Sialyl LewisA. Utilizing MGS5 for detection, Neu5Gc-Sialyl LewisA was found to be significantly expressed in numerous cancer tissues, such as breast, liver and pancreas, with minimal staining observed across normal tissue types. Neu5Gc-Sialyl LewisA also demonstrated the ability to be used as an early detection biomarker for pancreatic cancer. Tissue samples of low-grade or high-grade pancreatic intraepithelial neoplasia (PanIN) lesions displayed a 2-fold increase in the binding of the MGS5 peptide compared to normal healthy pancreas. Read Less... This webinar will discuss a liposome-based immunotherapy (“Targeted Antigen Loaded Liposomes” TALL) that consists of three modular components: 1) pegylated stealth phospholipid layer, 2) an encapsulated synthetic immunogenic MHC class I restricted peptide derived from the measles virus and 3) MGS5 on the external surface for tumor targeting. MGS5 binds to the surface of the cancer cells via Neu5Gc-Sialyl LewisA and is subsequently internalized allowing for the internalization of the liposome and the release of the encapsulated antigenic peptide. This in turn elicits a robust immune response. TALL, in combination with an anti-programmed cell death protein 1 (PD-1) inhibitor, results in a 10-fold reduction in tumor burden in mice bearing orthotopic breast and pancreatic tumors, compared to using anti-PD-1 alone. Join this webinar to learn not only how MGS5 is a novel peptide for the detection of Neu5Gc- Sialyl LewisA, but it can also serve as a therapeutically relevant cancer targeting agent allowing for the delivery of therapeutics.

Throughout this session, we will delve into the report's key findings, providing an in-depth look at the current health status of the nation. Our experts will discuss how the effective integration of data and healthtech technology, as offered by dacadoo, can transform these insights into compelling wellness narratives and impactful strategies. This is a unique opportunity to hear firsthand how relevant and intelligently analyzed data can make a significant difference in the health and wellness sector. Join us for an informative and enriching conversation that promises to inspire and offer valuable insights into the future of digital health and life insurance.